A randomized, comparative trial of a potassium-competitive acid blocker (AZD0865) and esomeprazole for the treatment of patients with nonerosive reflux disease

American Journal of Gastroenterology

Volumn 103, Issue 1, 2008, Pages 20-26

  Dent, John ^a   Kahrilas, Peter J ^b   Hatlebakk, Jan ^c   Vakil, Nimish ^d   Denison, Hans ^e   Franzén, Stefan ^e   Lundborg, Per ^e  

^a ROYAL ADELAIDE HOSPITAL   (Australia)

^b NORTHWESTERN UNIVERSITY   (United States)

^c HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^d UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^e ASTRAZENECA R AND D   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

8 (2,6 DIMETHYLBENZYLAMINO) N (2 HYDROXYETHYL) 2,3 DIMETHYLIMIDAZO[1,2 A]PYRIDINE 6 CARBOXAMIDE; ESOMEPRAZOLE; POTASSIUM COMPETITIVE ACID BLOCKER;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ENDOSCOPY; ESOPHAGUS PH; FEMALE; GASTROESOPHAGEAL REFLUX; HEADACHE; HEARTBURN; HELICOBACTER PYLORI; HUMAN; INCIDENCE; LIVER DYSFUNCTION; LIVER FUNCTION TEST; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STATISTICAL ANALYSIS; STOMACH PH;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ENDOSCOPY, GASTROINTESTINAL; ENZYME INHIBITORS; ESOPHAGUS; FEMALE; FOLLOW-UP STUDIES; GASTRIC ACIDITY DETERMINATION; GASTROESOPHAGEAL REFLUX; HEARTBURN; HUMANS; HYDROGEN-ION CONCENTRATION; IMIDAZOLES; MALE; MIDDLE AGED; OMEPRAZOLE; PYRIDINES; QUESTIONNAIRES; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 37849036310     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1111/j.1572-0241.2007.01544.x     Document Type: Article

References (18)

1. van Pinxteren B, Numans ME, Bonis PA, et al. Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. Cochrane Database Syst Rev 2004 4 CD00Z095.
2. Holstein B, Florentzson M, Andersson M, et al. AZD0865, a potassium-competitive acid blocker (P-CAB), has a long duration of effect in the rat. Am J Gastroenterol 2004 99 (Suppl 10 S8.
3. Holstein B, Holmberg A, Florentzson M, et al. AZD0865 - a new potassium-competitive acid blocker -exhibits maximal gastric antisecretory effects from first dose. Gastroenterology 2004 126 : A 334.
4. Holstein B, Holmberg A, Florentzson M, et al. AZD0865, a potassium-competitive acid blocker (P-CAB), provides predictable inhibition of acid secretion with repeated dosing in the dog. Eur J Pharm Sci 2004 23 (Suppl 1 S8.
5. Nilsson C, Albrektson E, Rydholm H, et al. Tolerability, pharmacokinetics and effects on gastric acid secretion after single oral doses of the potassium-competitive acid blocker AZD0865 in healthy male subjects. Gut 2005 54 : A106.
6. Shaw MJ, Talley NJ, Beebe TJ, et al. Initial validation of a diagnostic questionnaire for gastroesophageal reflux disease. Am J Gastroenterol 2001 96 : 52 7.
7. Kulig M, Nocon M, Vieth M, et al. Risk factors of gastroesophageal reflux disease: Methodology and first epidemiological results of the ProGERD study. J Clin Epidemiol 2004 57 : 580 9.
8. Armstrong D, Talley NJ, Lauritsen K, et al. The role of acid suppression in patients with endoscopy-negative reflux disease: The effect of treatment with esomeprazole or omeprazole. Aliment Pharmacol Ther 2004 20 : 413 21.
9. Katz PO, Castell DO, Levine D. Esomeprazole resolves chronic heartburn in patients without erosive oesophagitis. Aliment Pharmacol Ther 2003 18 : 875 82.
10. Galmiche JP, Barthelemy P, Hamelin B. Treating the symptoms of gastro-oesophageal reflux disease: A double-blind comparison of omeprazole and cisapride. Aliment Pharmacol Ther 1997 11 : 765 73.
11. Carlsson R, Dent J, Watts R, et al. Gastro-oesophageal reflux disease in primary care: An international study of different treatment strategies with omeprazole. International GORD Study Group. Eur J Gastroenterol Hepatol 1998 10 : 119 24.
12. Miner P Jr., Orr W, Filippone J, et al. Rabeprazole in nonerosive gastroesophageal reflux disease: A randomized placebo-controlled trial. Am J Gastroenterol 2002 97 : 1332 9.
13. Richter JE, Kovacs TO, Greski-Rose PA, et al. Lansoprazole in the treatment of heartburn in patients without erosive oesophagitis. Aliment Pharmacol Ther 1999 13 : 795 804.
14. Lind T, Havelund T, Carlsson R, et al. Heartburn without oesophagitis: Efficacy of omeprazole therapy and features determining therapeutic response. Scand J Gastroenterol 1997 32 : 974 9.
15. Richter JE, Peura D, Benjamin SB, et al. Efficacy of omeprazole for the treatment of symptomatic acid reflux disease without esophagitis. Arch Intern Med 2000 160 : 1810 6.
16. McColl E, Junghard O, Wiklund I, et al. Assessing symptoms in gastroesophageal reflux disease: How well do clinicians' assessments agree with those of their patients? Am J Gastroenterol 2005 100 : 11 8.
17. U. S. Food and Drug Administration. Center for Drug Evaluation and Research. Clinical White Paper for the CDER-PHRMA-AASLD Conference on Drug-Induced Liver Disease: A National and Global Problem. Available at : http://www.fdagov/cder/livertox/clinical.pdf 2000. Accessed September 3, 2007.
18. Parsons ME, Keeling DJ. Novel approaches to the pharmacological blockade of gastric acid secretion. Expert Opin Investig Drugs 2005 14 : 411 21.